Bristol-Myers Squibb Company logo

Bristol-Myers Squibb Company (BMY)

Market Closed
5 Dec, 20:00
NYSE NYSE
$
52. 15
+0.2
+0.38%
$
100.26B Market Cap
- P/E Ratio
2.4% Div Yield
12,842,581 Volume
- Eps
$ 51.95
Previous Close
Day Range
51.69 52.51
Year Range
42.52 63.33
Want to track BMY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 60 days
2 Pharma Stocks to Buy Hand Over Fist This Month

2 Pharma Stocks to Buy Hand Over Fist This Month

Pfizer and Bristol Myers have faced issues recently that have led to poor stock market performances. However, both drugmakers are spinning their innovative wheels and look likely to bounce back.

Fool | 1 year ago
Bristol Myers (BMY) Loses 20.5% YTD: Should You Retain or Fold?

Bristol Myers (BMY) Loses 20.5% YTD: Should You Retain or Fold?

Bristol Myers (BMY) faces an uphill struggle as top drugs face challenges. We advise investors to steer clear for the time being.

Zacks | 1 year ago
5 Under $50 Dividend Stocks to Buy Now

5 Under $50 Dividend Stocks to Buy Now

24/7 Insights Dividend stocks offer investors the opportunity to increase investment total return.

247wallst | 1 year ago
Bristol Myers Squibb (BMY) Suffers a Larger Drop Than the General Market: Key Insights

Bristol Myers Squibb (BMY) Suffers a Larger Drop Than the General Market: Key Insights

In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $40.75, denoting a -0.9% change from the preceding trading day.

Zacks | 1 year ago
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It

Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It

Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks | 1 year ago
Dividend Harvesting Portfolio Week 175: $17,500 Allocated, $1,566.24 In Projected Dividends

Dividend Harvesting Portfolio Week 175: $17,500 Allocated, $1,566.24 In Projected Dividends

Markets started the 2nd half of 2024 strong, with S&P up 1.69% and Nasdaq up 3.29%. Earnings season approaching, with the banking sector first, followed by the Magnificent Seven. Dividend Harvesting Portfolio hits all-time high, generating $44.41 in dividend income in the first week of July.

Seekingalpha | 1 year ago
3 Undervalued Stocks Ready for a Breakout This Summer

3 Undervalued Stocks Ready for a Breakout This Summer

As the second half of 2024 unfolds, main Wall Street indices are reaching new highs. The Nasdaq 100 index soared more than 20% year-to-date, and the S&P 500 saw an all-time high with a 16% surge.

Investorplace | 1 year ago
3 High-Yield S&P 500 Dividend Stocks That You Can Buy With $100 Right Now

3 High-Yield S&P 500 Dividend Stocks That You Can Buy With $100 Right Now

Bristol Myers Squibb upset investors with a big acquisition-related expense, but its pharmaceutical business is stronger than ever. Vici Properties is a real estate investment trust that collects rent from some of the largest casino operators in Las Vegas.

Fool | 1 year ago
Top Dividend Stocks To Buy In July 2024? 2 In Focus

Top Dividend Stocks To Buy In July 2024? 2 In Focus

Dividend stocks for your July 2024 watchlist.

Stockmarket | 1 year ago
3 Defensive Stocks to Buy During the Market Dip

3 Defensive Stocks to Buy During the Market Dip

Despite markets reaching new heights recently, many defensive stocks with reliable and consistent demand are still experiencing their own market dip. They have pulled back as investors repositioned into the artificial intelligence (AI) trend.

Investorplace | 1 year ago
Jump on These 5 Ultra-High-Yield Pound-the-Table Stock Buys Now

Jump on These 5 Ultra-High-Yield Pound-the-Table Stock Buys Now

24/7 Insights Wounded blue chip stocks can offer huge total return potential.

247wallst | 1 year ago
Bristol Myers to pay $2.7 mln to settle Israel anti-competition charges

Bristol Myers to pay $2.7 mln to settle Israel anti-competition charges

Bristol Myers Squibb has agreed to pay 10 million shekels ($2.7 million) in Israel to settle a potential case over its blocking of a generic version for anti-cancer drug Imnovid, Israel's Competition Authority said on Monday.

Reuters | 1 year ago
Loading...
Load More